TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04332497

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen, Dorifen®; Fentanyl, Talinat®, ''Patient Controlled Analgesia Device''
Description: Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen, Dorifen®; Fentanyl, Talinat®, ''Patient Controlled Analgesia Device''
Description: Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit
Study: NCT02327390

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lymph node
Description: Undergo surgery to remove a melanoma-draining lymph node for generation of X-ACT cells in the laboratory

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: X-ACT
Description: Administered as an IV infusion
Study: NCT03020134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravidasvir
Description: Ravidasvir tablet administered orally 200mg QD on day 1, 13 - 23

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danoprevir
Description: Danoprevir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01027234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8418
Description: Single oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single oral dose
Study: NCT03265002

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ingestion of 500ml water with 50ml lemon juice and 20g dextrose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: Ingestion of 500ml water with 50ml lemon juice and 20g inulin

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Psyllium
Description: Ingestion of 500ml water with 50ml lemon juice and 20g psyllium

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inulin and psyllium
Description: Ingestion of 500ml water with 50ml lemon juice and 20g inulin and 20g psyllium
Study: NCT02893865

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure
Description: Continuous positive airway pressure treatment during three months with adherence recording

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-continuous positive airway pressure
Description: Sham-continuous positive airway pressure during three months with adherence recording
Study: NCT05064020

Intervention type: DRUG
Intervention: Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY]
Description: Administer BIC/FTC/TAF 50/200/25 mg tablet by mouth once a day from day 1 to168.

Intervention type: DRUG
Intervention: Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY]
Description: Administer BIC/FTC/TAF 50/200/25 mg tablet by mouth once a day from day 1 to168.
Study: NCT02617394

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diaphragm scanning - traditional method first
Description: The first (pre-block) diaphragm scan with ultrasound will be done on both sides using the liver (right side) and spleen (left side) as acoustic windows. The second (post-block) diaphragm scan will be done on both sides using a novel method in which lung sliding is used as a guide to identify the diaphragm and quantify diaphragm thickening upon respiration.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragm scanning - novel method first
Description: The first (pre-block) diaphragm scan with ultrasound will be done on both sides using a novel method in which lung sliding is used as a guide to identify the diaphragm and quantify diaphragm thickening upon respiration. The second (post-block) diaphragm scan will be done will be done on both sides using the liver (right side) and spleen (left side) as acoustic windows.
Study: NCT01549808

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobilization
Description: The patients are mobilized according to the mobilization protocol. The training concist of balance, muscle strength and staying power. Before the mobilization the patients ability to mobilization is evaluated according to contradictions and pre screening (exh 2,3). The primary nurse and the physiotherapist evaluate and allocate patients to mobilization stage. All patients is mobilized minimum 3 times at day (exh 2) and is supported as a minimum of two persons. Before each activity the patient must have a rest period of ½ hour. The patients security during mobilization is registried (exh 1,3). The mobilization stops if patients security is affected. During walk patients is followed by a chair, in order to prevent or cushion a fall.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobilization
Description: sitting, standing and walking
Study: NCT00686426

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dairy Foods
Description: Adequate dairy (\> 3 standard daily servings)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dairy Foods
Description: \< 1 standard dairy serving/day
Study: NCT00904462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidoderm
Description: Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch
Description: Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
Study: NCT00937144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viagra (Sildenafil)
Description: Viagra treatment to patients with sickle cell anemia.
Study: NCT02040376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID.
Study: NCT03125343

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Surgery according to recommendations from the multidisciplinary group in patients that prefer surgery to a watch and wait strategy
Study: NCT03926624

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decitabine
Description: Decitabine
Study: NCT04511364

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical imaging is performed during the 24 and 60 month follow-up visits
Description: X-ray and DXA scan
Study: NCT03307863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine-Implant
Description: Women with epilepsy using carbamazepine for at least 3 months will have an etonogestrel-releasing implant inserted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate-Implant
Description: Women with epilepsy using carbamazepine for at least 3 months will have an etonogestrel-releasing implant inserted

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Implant
Description: Women without epilepsy and not using an anti-epileptic drug will have an etonogestrel-releasing implant inserted
Study: NCT03993171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gold nanocrystals
Description: CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gold nanocrystals
Description: CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gold nanocrystals
Description: CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.
Study: NCT03926624

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitoxantrone
Description: Mitoxantrone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: Fludarabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Idarubicin
Description: Idarubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venetoclax
Description: Venetoclax

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cladribine
Description: Cladribine
Study: NCT04612868

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AEYE Software Device
Description: Eligible participants will undergo the following procedures:~* Photographic imaging of each eye using a funduscopy camera device. Images obtained will be sent to the AEYE-DS software for analysis.~* Additional photographic and Optical Coherence Tomography (OCT) images will be obtained using a second funduscopy/OCT camera device. Images obtained will be sent to a professional reading center for analysis.~* All study subjects will have their pupils dilated using dilation drops.
Study: NCT00505336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Description: oral Eplerenone titrated to 50mg for duration of 12 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No additional treatment
Description: normal disease modifying therapy for heart failure i.e. ACE-I, beta blockers

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: oral Atorvastatin 40mg
Study: NCT04618250

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SOFIA model
Description: A mandatory two day course for general practitioners assigned to the intervention group A prolonged consultation at the general practitioner Use of an individual care plan
Study: NCT03398876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oromucosal Nicotine Spray (ONS)
Description: Participants will receive oral dose of oromucosal nicotine spray (ONS).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oromucosal Nicotine Spray (ONS)
Description: Participants will receive oral dose of oromucosal nicotine spray (ONS).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oromucosal Nicotine Spray (ONS)
Description: Participants will receive oral dose of oromucosal nicotine spray (ONS).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oromucosal Nicotine Spray (ONS)
Description: Participants will receive oral dose of oromucosal nicotine spray (ONS).
Study: NCT03993171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gold nanocrystals
Description: CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.
Study: NCT03125343

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Study: NCT00937144

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02984150

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dodecanoic acid
Study: NCT04427709

Intervention type: DRUG
Group type: OTHER
Intervention: Oxytocin
Description: Intramuscular injection of Oxytocin (Pitocin®)

Intervention type: DRUG
Group type: OTHER
Intervention: Oxytocin
Description: Intramuscular injection of Oxytocin (Pitocin®)

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Intramuscular placebo injection

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Intramuscular placebo injection
Study: NCT04106466

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Summit RC+S DBS system
Description: Open label active Deep Brain Stimulation (DBS)
Study: NCT03125343

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Study: NCT04160091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX006
Description: Single intra-articular injection
Study: NCT03398876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oromucosal Nicotine Spray (ONS)
Description: Participants will receive oral dose of oromucosal nicotine spray (ONS).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oromucosal Nicotine Spray (ONS)
Description: Participants will receive oral dose of oromucosal nicotine spray (ONS).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Gum
Description: Participants will chew nicotine gum for 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Gum
Description: Participants will chew nicotine gum for 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Gum
Description: Participants will chew nicotine gum for 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Gum
Description: Participants will chew nicotine gum for 30 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarette
Description: Participants will smoke one cigarette as 10 puffs for 3 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarette
Description: Participants will smoke one cigarette as 10 puffs for 3 minutes.
Study: NCT02984150

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: saline
Study: NCT03398876

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarette
Description: Participants will smoke one cigarette as 10 puffs for 3 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarette
Description: Participants will smoke one cigarette as 10 puffs for 3 minutes.
Study: NCT01581216

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 10 minute walk
Description: Patients who walk a distance ≤ 300 meters in the 6-minute walk test will make a 10 minute walk once a day for 5 days for 4 weeks in a 90-feet long corridor located at the palliative care unit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 20 minute walk
Description: Patients who walk 300-450 meters in the 6-minute walk test will make a 20 minute walk once a day for 5 days for 4 weeks in a 90-feet long corridor located at the palliative care unit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 30 minute walk
Description: Patients who walk a distance less than 450 meters in the 6-minute walk test will make a 30 minute walk once a day for 5 days for 4 weeks in a 90-feet long corridor located at the palliative care unit.
Study: NCT02208414

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NAET
Description: NAET with acupressure and/or chiropractic procedures with the participant holding crab and shrimp energy signature vial
Study: NCT02760173

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: perception of vertical after static roll-tilt over 5min
Description: subjects will indicate perceived direction of vertical after 5min of static whole-body roll-tilt.
Study: NCT01607333

Intervention type: DRUG
Intervention: Lamotrigine use
Description: Lamotrigine prescription during the study period

Intervention type: DRUG
Intervention: Lamotrigine use
Description: Lamotrigine prescription during the study period

Intervention type: DRUG
Intervention: Lamotrigine use
Description: Lamotrigine prescription during the study period
Study: NCT03319953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-041
Description: TAK-041 suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-041
Description: TAK-041 suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-041
Description: TAK-041 suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-041
Description: TAK-041 suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-041 placebo-matching suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-041 placebo-matching suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-041 placebo-matching suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-041 placebo-matching suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Second Generation Antipsychotics (SGA)
Description: Second generation antipsychotics included risperidone, paliperidone, iloperidone, quetiapine, olanzapine, ziprasidone, asenapine and lurasidone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Second Generation Antipsychotics (SGA)
Description: Second generation antipsychotics included risperidone, paliperidone, iloperidone, quetiapine, olanzapine, ziprasidone, asenapine and lurasidone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Second Generation Antipsychotics (SGA)
Description: Second generation antipsychotics included risperidone, paliperidone, iloperidone, quetiapine, olanzapine, ziprasidone, asenapine and lurasidone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Second Generation Antipsychotics (SGA)
Description: Second generation antipsychotics included risperidone, paliperidone, iloperidone, quetiapine, olanzapine, ziprasidone, asenapine and lurasidone.
Study: NCT02696733

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound-guided obturator nerve localization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine 2%
Description: local anesthetic used to block the obturator nerve

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% Natrium Chloratum with a 2nd generation cephalosporin
Study: NCT03459001

Intervention type: OTHER
Intervention: Tube Feeding Product
Description: a high calorie, high protein tube feed product consumed sole source per their physician's recommendation and per standard of care
Study: NCT01568450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Oxycodone XL 20mg(20mg once a day, fasted)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Oxycodone XL 20mg/day(20mg once a day, after high fat meal)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Oxycodone 20mg/day (10mg twice a day, fasted)
Study: NCT03648177

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IPGT
Description: Behavioral Intervention for Patients with Chronic Pain

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Standard Care
Study: NCT04160091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX006
Description: Single intra-articular injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Single intra-articular injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Single intra-articular injection
Study: NCT01003730

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ventilator settings
Description: Active Comparison of three different parameters of ventilator settings. Results of arterial blood gases and cytokine levels.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ventilator settings
Description: Active Comparison of three different parameters of ventilator settings. Results of arterial blood gases and cytokine levels.
Study: NCT01795495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone hydrochloride
Description: This drug will be used in conjunction with remifentanil as an adjunct analgesic. Remifentanil + methadone (0.1 mg/kg IV over 15 minutes) just after induction of anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: This drug will be given with remifentanil as an adjunct analgesic. Remifentanil + magnesium (50 mg/kg bolus over 30 minutes followed by 10 mg/kg/hour).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Study: NCT01003730

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ventilator settings
Description: Active Comparison of three different parameters of ventilator settings. Results of arterial blood gases and cytokine levels.